Rivastigmine Transdermal Patch 4.6mg
Rivastigmine Transdermal Patch 4.6mg/24 hours is a prescription cholinesterase-inhibitor patch used for the treatment of dementia associated with Alzheimer’s disease and mild-to-moderate dementia associated with Parkinson’s disease. The patch provides continuous delivery of Rivastigmine through the skin over 24 hours and is commonly used as the initial treatment strength before gradual dose adjustment according to tolerability and clinical response.
Price: From $100.00
Category: Neurology
Brand: Rivastigmine
SKU: RTP46-1267
Availability: In Stock
Active Ingredient: Rivastigmine 4.6mg per 24 hours
Dosage Form: Tablets
Indication & Clinical Uses
Dementia associated with Alzheimer’s disease Mild Alzheimer’s disease dementia Moderate Alzheimer’s disease dementia Severe Alzheimer’s disease dementia as part of a professionally titrated treatment plan Mild-to-moderate dementia associated with Parkinson’s disease Symptomatic management of cognitive impairment associated with dementia Support for memory, thinking and daily-function symptoms in eligible patients Initial Rivastigmine transdermal therapy Restarting Rivastigmine treatment after an interruption longer than three days Lower maintenance dosing in selected patients with mild-to-moderate liver impairment Lower maintenance dosing in selected patients with low body weight or dose-related intolerance
Dosage & Administration Guidance
Use Rivastigmine Transdermal Patch 4.6mg/24 hours only according to the prescription and caregiver instructions provided by the prescriber and dispensing pharmacist. The recommended initial transdermal dose is one 4.6mg/24-hour patch applied once daily. Replace the patch with a new patch every 24 hours. Apply only one patch at a time. Always remove the previous day’s patch before applying a new patch. Check the patient’s skin carefully because a previously applied patch may be hidden under clothing. Do not apply multiple patches to achieve a higher dose unless an explicit, product-specific instruction has been issued by the prescriber. Increase the dose only after a minimum of four weeks at the previous dose and only when that dose has been tolerated. For mild-to-moderate Alzheimer’s disease and Parkinson’s disease dementia, maintenance treatment may be increased to 9.5mg/24 hours or 13.3mg/24 hours when professionally appropriate. For severe Alzheimer’s disease, the labeled effective strength is 13.3mg/24 hours after appropriate titration. Do not use a dose higher than 13.3mg/24 hours. Higher doses do not provide appreciable additional benefit and are associated with more adverse reactions. If treatment is interrupted for three days or fewer, the prescriber may advise restarting with the same or a lower patch strength. If treatment is interrupted for more than three days, contact the prescriber before restarting. Treatment should generally be restarted with the 4.6mg/24-hour patch. Apply the patch to clean, dry, hairless, intact and healthy skin. Preferred locations include the upper or lower back. The upper arm or chest may be used when the back is not accessible. Do not apply the patch to red, irritated, inflamed, cut or damaged skin. Do not apply it to skin where cream, lotion, oil or powder has recently been used. Do not cut, fold, damage or modify the patch. Press the patch firmly in place for approximately 30 seconds, particularly around its edges. Change the application site every day. Do not apply a new patch to the exact same skin location for at least 14 days. The patch may generally remain in place during normal bathing. Avoid prolonged exposure to excessive sunlight, heating pads, electric blankets, hot tubs, saunas, heat lamps and other external heat sources. If a patch falls off, apply a new patch immediately and replace it at the regular time the following day. Carefully monitor patients weighing less than 50kg for excessive nausea, vomiting, reduced appetite, weight loss and other toxicities. The 4.6mg/24-hour patch may be considered as both an initial and maintenance dose in patients with mild-to-moderate liver impairment. Monitor the patient’s weight, hydration, heart rate, gastrointestinal symptoms, skin reactions, mobility and ability to continue driving or operating machinery. Rivastigmine dosing and administration requirements are defined in current prescribing information.
Storage & Handling
Keep each Rivastigmine patch inside its individual sealed pouch until immediately before use. Recommended Storage Temperature: 20°C to 25°C / 68°F to 77°F. Temporary temperature excursions may be permitted between 15°C and 30°C / 59°F and 86°F according to controlled-room-temperature requirements. Protect the patches from excessive heat. Do not leave patches in direct sunlight, inside a hot vehicle or near a heating appliance. Do not refrigerate or freeze unless the specific manufacturer label expressly requires it. Do not open the pouch until ready to apply the patch. Do not use a patch if its pouch has been opened, damaged or improperly sealed. Do not use a patch that is cut, torn, folded, dried out, contaminated or otherwise altered. Keep unused and used patches away from children and pets. After removal, fold the used patch in half with its adhesive surfaces pressed together. Dispose of used patches according to the dispensing-pharmacy instructions and applicable local requirements. Do not flush a patch unless the supplied manufacturer or pharmacy disposal instructions specifically direct that method. Official labeling requires controlled room-temperature storage and retention in the sealed pouch until use.
How to Use & Dosage Guidance
- Confirm the Prescribed Strength: Confirm that the prescription, carton, individual pouch and patch label identify Rivastigmine 4.6mg/24 hours before applying the patch.
- Remove the Previous Patch: Check the patient’s skin carefully and remove the previous day’s patch before opening or applying a new patch. Only one Rivastigmine patch must be worn at a time.
- Select an Appropriate Application Site: Choose clean, dry, hairless, intact and healthy skin on the upper or lower back, upper arm or chest. The upper or lower back may be preferred where accidental removal is less likely.
- Inspect the Skin: Do not apply the patch to skin that is red, irritated, inflamed, cut or damaged. Do not apply it over an area recently treated with cream, lotion, oil, powder or another topical product.
- Open the Sealed Pouch: Open the pouch only when ready to apply the patch. Do not use the patch if the pouch seal is broken or if the patch is cut, damaged, folded or altered.
- Apply the Patch Firmly: Remove the protective liner without touching the adhesive more than necessary. Place the patch flat against the selected skin area and press it firmly for approximately 30 seconds, especially around the edges.
- Wear for 24 Hours: Keep the patch in place for 24 hours unless the prescriber provides different instructions. Replace it with a new patch at approximately the same time each day.
- Rotate the Application Site: Use a different skin location each day to reduce irritation. Do not apply a new patch to the exact same location for at least 14 days.
- Avoid Excessive External Heat: The patch may be worn during normal bathing, but avoid prolonged exposure to heating pads, electric blankets, saunas, hot tubs, heat lamps, solariums or excessive direct sunlight.
- Remove and Dispose Safely: After removing the used patch, fold it in half with the adhesive surfaces pressed together. Dispose of it safely where children, pets and other people cannot reach it.
- Manage a Fallen or Missed Patch: If the patch falls off or a dose is missed, apply a new patch immediately. Replace that patch at the regular application time on the following day.
- Restart Carefully After an Interruption: If treatment has been interrupted for more than three days, contact the prescriber before applying another patch. Treatment may need to restart with the 4.6mg/24-hour strength.
Safety Warnings & Precautions
- Use only according to the prescription.
- Apply only one Rivastigmine patch at a time.
- Remove the previous patch before applying a new patch.
- Accidental application of multiple patches can cause serious overdose.
- Medication errors involving multiple patches have resulted in hospitalization.
- Rare deaths have been reported following serious patch medication errors.
- Caregivers should inspect the patient’s skin before applying each new patch.
- Do not cut the patch.
- Do not use a damaged or altered patch.
- Do not use a patch from an opened or damaged pouch.
- Apply only to intact and healthy skin.
- Do not apply to red or irritated skin.
- Do not apply to broken or cut skin.
- Do not apply over cream, lotion, oil or powder.
- Change the application site every day.
- Do not reuse the exact same skin location within 14 days.
- Avoid prolonged exposure to external heat sources.
- Heating pads may increase medication absorption.
- Electric blankets may increase medication absorption.
- Avoid prolonged sauna or hot-tub exposure.
- Avoid excessive direct sunlight while wearing the patch.
- Significant nausea, vomiting or diarrhea may occur.
- Prolonged vomiting or diarrhea may cause dehydration.
- Monitor for reduced appetite and weight loss.
- Patients weighing less than 50kg may experience more dose-related toxicity.
- Do not increase the patch strength before the previous strength has been tolerated for at least four weeks.
- Do not use a dose higher than 13.3mg/24 hours.
- Contact the prescriber if treatment is interrupted for more than three days.
- Do not restart the previous maintenance strength after an interruption longer than three days without professional instructions.
- Improper restarting may cause severe vomiting and serious complications.
- Monitor application-site reactions.
- Discontinue and seek professional advice when a reaction spreads beyond the patch boundary.
- Seek advice when redness, swelling, papules or blisters become increasingly severe.
- Seek advice when a skin reaction does not substantially improve within 48 hours after patch removal.
- Allergic contact dermatitis may prevent future use of transdermal or oral Rivastigmine.
- Rivastigmine may worsen tremor or other Parkinsonian symptoms.
- Rivastigmine may increase seizure potential.
- Monitor patients with a seizure history.
- Rivastigmine may increase gastric-acid secretion.
- Monitor patients with a history of stomach ulcers.
- Monitor for black stools, vomiting blood or other gastrointestinal-bleeding symptoms.
- Additional caution is required with concurrent NSAID treatment.
- Rivastigmine may slow the heart rate.
- Use caution in patients with sick sinus syndrome.
- Use caution in patients with supraventricular conduction disorders.
- Monitor patients with a history of fainting or unexplained falls.
- Use caution with medicines that reduce heart rate.
- Use caution in patients with asthma.
- Use caution in patients with obstructive pulmonary disease.
- Medicines increasing cholinergic activity may cause urinary obstruction.
- Tell the surgical and anesthesia team that Rivastigmine is being used.
- Rivastigmine may exaggerate succinylcholine-type muscle relaxation during anesthesia.
- Dementia and Rivastigmine-related adverse effects may impair driving.
- Regularly assess the patient’s ability to drive or operate machinery.
- Use additional caution in mild-to-moderate liver impairment.
- The 4.6mg/24-hour patch may be required as the maintenance dose in liver impairment.
- Safety and effectiveness have not been established in pediatric patients.
- Inform the prescriber about pregnancy, planned pregnancy or breastfeeding.
- Keep all unused and used patches away from children.
- Keep all unused and used patches away from pets.
- Fold used patches adhesive-side inward before disposal.
- Seek urgent medical care for severe vomiting, severe diarrhea, dehydration, fainting, very slow heart rate, breathing difficulty, seizure, severe weakness, confusion or loss of consciousness.
- These warnings reflect labeled risks involving medication errors, gastrointestinal reactions, skin sensitization and increased cholinergic activity.
Contraindications
- Known hypersensitivity to Rivastigmine
- Known hypersensitivity to another carbamate derivative
- Known hypersensitivity to any component of the supplied patch formulation
- Previous application-site reaction to a Rivastigmine patch suggestive of allergic contact dermatitis
- The labeled contraindications are hypersensitivity to Rivastigmine, other carbamate derivatives or formulation components, and a history of patch reactions suggesting allergic contact dermatitis.
Drug Interactions
- Metoclopramide — concomitant use is not recommended because of the risk of additive extrapyramidal adverse reactions
- Beta-blockers — may produce additive slow heart rate, fainting or cardiac-conduction effects
- Atenolol — may increase the risk of clinically significant bradycardia when combined with Rivastigmine
- Metoprolol — may increase the risk of clinically significant bradycardia when combined with Rivastigmine
- Propranolol — may increase the risk of slow heart rate and fainting
- Other medicines that reduce heart rate — may increase bradycardia or syncope risk
- Other cholinesterase inhibitors — may increase cholinergic adverse effects
- Cholinomimetic medicines — may increase nausea, vomiting, diarrhea, sweating, salivation, slow heart rate and other cholinergic effects
- Bethanechol — may produce additive cholinergic effects
- Anticholinergic medicines — Rivastigmine may interfere with their therapeutic activity
- Oxybutynin — anticholinergic effects may oppose Rivastigmine activity
- Tolterodine — anticholinergic effects may oppose Rivastigmine activity
- Succinylcholine-type neuromuscular blockers — Rivastigmine may exaggerate muscle relaxation during anesthesia
- Nonsteroidal anti-inflammatory drugs — may increase concern for stomach ulcers or gastrointestinal bleeding in susceptible patients
- Aspirin used at anti-inflammatory doses — may increase gastrointestinal irritation or bleeding concerns
- Medicines associated with extrapyramidal symptoms — may increase movement-related adverse effects
- The principal labeled interaction categories are metoclopramide, beta-blockers, cholinomimetic medicines and anticholinergic medicines. Rivastigmine can also affect succinylcholine-type muscle relaxation during anesthesia.
Potential Side Effects
- Nausea
- Vomiting
- Diarrhea
- Reduced appetite
- Anorexia
- Weight loss
- Dehydration associated with prolonged vomiting or diarrhea
- Application-site redness
- Application-site erythema
- Application-site itching
- Application-site irritation
- Application-site rash
- Application-site swelling
- Application-site blistering
- Allergic contact dermatitis
- Disseminated allergic dermatitis
- Dizziness
- Headache
- Insomnia
- Anxiety
- Depression
- Agitation
- Aggression
- Hallucinations
- Nightmares
- Somnolence
- Fatigue
- Weakness
- Fall
- Fainting
- Slow heart rate
- Abdominal pain
- Upper-abdominal pain
- Increased gastric-acid secretion
- Peptic-ulcer symptoms
- Gastrointestinal bleeding
- Urinary incontinence
- Urinary obstruction
- Urinary-tract infection
- Tremor
- Worsening Parkinsonian symptoms
- Reduced movement
- Bradykinesia
- Cogwheel rigidity
- Dyskinesia
- Gait disturbance
- Psychomotor hyperactivity
- Seizure
- Hypertension
- Breathing difficulty in susceptible patients
- Severe hypersensitivity reaction
- Stevens–Johnson syndrome reported during postmarketing use
- Common and clinically important reactions are documented in current Rivastigmine labeling.
Frequently Asked Questions
- What is Rivastigmine Transdermal Patch 4.6mg?
- It is a prescription patch that delivers 4.6mg of Rivastigmine through the skin over 24 hours.
- What is the patch used for?
- It is used to treat dementia associated with Alzheimer’s disease and mild-to-moderate dementia associated with Parkinson’s disease.
- Does Rivastigmine cure dementia?
- No. Rivastigmine may help manage cognitive and functional symptoms, but it does not cure Alzheimer’s disease, Parkinson’s disease or the underlying neurodegenerative process.
- Is 4.6mg the starting strength?
- Yes. The 4.6mg/24-hour patch is the labeled initial transdermal dose.
- How often is the patch applied?
- Apply one patch once daily and replace it with a new patch every 24 hours.
- Can two patches be worn together?
- No. Only one Rivastigmine patch should be worn at a time unless a prescriber has issued an explicit, product-specific instruction. The old patch must be removed before applying a new one.
- Where should the patch be applied?
- Apply it to clean, dry, hairless, intact and healthy skin on the upper or lower back, upper arm or chest.
- Can the patch be applied to irritated skin?
- No. Do not apply the patch to red, irritated, inflamed, cut or damaged skin.
- Can lotion be used before applying the patch?
- Do not apply the patch to an area where cream, lotion, oil or powder has recently been used because this may affect adhesion.
- How long should the patch be pressed onto the skin?
- Press the patch firmly against the skin for approximately 30 seconds, ensuring that the edges adhere properly.
- Can the patch be cut?
- No. Do not cut, damage, fold or otherwise alter the patch.
- Can the patch be worn while bathing?
- Yes. It may generally be worn during normal bathing, but prolonged external heat exposure should be avoided.
- Which heat sources should be avoided?
- Avoid prolonged exposure to heating pads, electric blankets, saunas, hot tubs, heat lamps, solariums and excessive direct sunlight.
- How often should the application site be changed?
- Change the application site every day. Do not use the exact same skin location again for at least 14 days.
- What should be done if the patch falls off?
- Apply a new patch immediately and replace it the next day at the usual application time.
- What happens if treatment is stopped for more than three days?
- Contact the prescriber before restarting. Treatment is generally restarted with the 4.6mg/24-hour strength and titrated again when appropriate.
- When can the dose be increased?
- The dose may be increased only after a minimum of four weeks at the previous strength and only when that strength has been tolerated.
- What are the most common side effects?
- Common effects include nausea, vomiting, diarrhea, decreased appetite, weight loss, dizziness, headache and skin reactions at the application site.
- Which skin reactions require professional review?
- Contact the prescriber if redness, swelling, itching, papules or blisters spread beyond the patch area, become increasingly severe or do not improve substantially within 48 hours after removal.
- Can the patch affect heart rate?
- Yes. Rivastigmine may slow the heart rate and requires additional caution in patients with cardiac conduction problems or medicines that reduce heart rate.
- Can Rivastigmine cause weight loss?
- Yes. Reduced appetite, nausea, vomiting, diarrhea and weight loss can occur. Body weight should be monitored, particularly in lower-weight patients.
- Can Rivastigmine worsen Parkinson’s symptoms?
- Rivastigmine may aggravate or induce extrapyramidal symptoms, including tremor or worsening Parkinsonian symptoms, in some patients.
- How should a used patch be discarded?
- Fold the used patch in half with the adhesive sides pressed together and dispose of it securely away from children, pets and other people.
- How should unused patches be stored?
- Keep each patch inside its sealed pouch at controlled room temperature until it is ready to be used.
Medically reviewed by CureHealth Clinical Review Board. Compliant with standard US pharmacy reference guidelines.